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Abstract
Background: This document describes a research protocol for a study designed to estimate the impact of
implementing a reminder system for medical providers on the use of isoniazid preventative therapy (IPT) for adults
living with HIV in western Kenya. People living with HIV have a 5% to 10% annual risk of developing active tuberculosis
(TB) once infected with TB bacilli, compared to a 5% lifetime risk in HIV-negative people with latent TB infection.
Moreover, people living with HIV have a 20-fold higher risk of dying from TB. A growing body of literature suggests
that IPT reduces overall TB incidence and is therefore of considerable benefit to patients and the larger community.
However, in 2009, of the estimated 33 million people living with HIV, only 1.7 million (5%) were screened for TB, and
about 85,000 (0.2%) were offered IPT.
Methods/Design: This study will examine the use of clinical decision-support reminders to improve rates of
initiation of preventative treatment in a TB/HIV co-morbid population living in a TB endemic area. This will be a
pragmatic, parallel-group, cluster-randomized superiority trial with a 1:1 allocation to treatment ratio. For the trial, 20
public medical facilities that use clinical summary sheets generated from an electronic medical records system will
participate as clusters. All HIV-positive adult patients who complete an initial encounter at a study cluster and at least
one return encounter during the study period will be included in the study cohort. The primary endpoint will be IPT
prescription at 3 months post the initial encounter. We will conduct both individual-level and cluster-level analyses.
Due to the nature of the intervention, the trial will not be blinded. This study will contribute to the growing evidence
base for the use of electronic health interventions in low-resource settings to promote high-quality clinical care,
health system optimization and positive patient outcomes.
Trial registration: ClinicalTrials.gov NCT01934309, registered 29 August 2013.
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Background
People living with HIV have a 5% to 10% annual risk of
developing tuberculosis (TB) disease once infected with
TB bacilli, compared to a 5% lifetime risk in HIV-negative
people with latent TB infection. Moreover, people living
with HIV have a 20-fold higher risk of dying from TB [1].
Active TB disease occurs at any stage of HIV infection and
is often the first recognized presentation of the underlying
viral infection [2,3]. As such, routinely screening for TB
during HIV care creates important opportunities to diag-
nose and promptly treat active disease, and also to identify
those without active TB disease who are eligible for iso-
niazid preventative therapy (IPT) [4]. A growing body of
literature suggests that IPT reduces overall TB incidence
and is therefore of considerable benefit to patients and
the larger community [5]. For these reasons, the World
Health Organization recommends routine, repeated clini-
cal screening for active TB disease among all people living
with HIV and the provision of either treatment for active
disease or IPT for asymptomatic patients to mitigate the
risk of developing active TB [6].
However, in 2009, of the estimated 33 million peo-
ple living with HIV, only 1.7 million (5%) were screened
for TB, and about 85,000 (0.2%) were offered IPT [7].
Greatly improving TB screening, diagnosis and treatment
for people living with HIV will require deployment of
an effective means of triaging and monitoring this group
of patients. While the use of alerts and reminders and
associated health informatics solutions to enhance health
service delivery is generally well described, this study, to
our knowledge, is the first to look at the use of clinical
decision-support reminders to directly improve rates of
TB screening and initiation of preventative treatment in a
TB/HIV co-morbid population.
Current study
Indiana University, Moi University School of Medicine,
the Moi Teaching and Referral Hospital and several other
medical school partners have created in western Kenya
an innovative and comprehensive response to HIV/AIDS
and other health challenges through their support of the
Kenyan Ministry of Health. This consortium, the Aca-
demicModel Providing Access to Healthcare (AMPATH),
promotes and fosters a comprehensive approach to
HIV/AIDS control that complements and enhances the
existing Kenyan Ministry of Health infrastructure. This
initiative supported by the United States Agency for
International Development (USAID) strengthens health
systems. It addresses food and income security needs,
delivers and monitors antiretroviral treatment, and fos-
ters prevention of HIV transmission through community-
based health education and prevention of maternal-to-
child transmission. Importantly, AMPATH works with
all levels of health providers, from the highest levels of
government to community health volunteers (CHVs), to
provide effective and culturally appropriate care.
The HIV burden in AMPATH’s catchment is large
(greater than 15% in some areas). There is a correspond-
ing large clinical enterprise in support of HIV care, which
collectively manages approximately 40,000 HIV patient
visits per month. Additionally, TB risks to this popula-
tion are substantial. Nationally, prevalence and incidence
rates of TB were estimated to be 299 and 272, respectively,
per 100,000 in 2012 [8]. Within the AMPATH network,
approximately 45% of patients with active TB have HIV
co-infection.
Objective
The overall research objective is to evaluate the impact
of implementing a reminder system for medical providers
(i.e., nurses, clinical officers, medical officers and con-
sultants) to improve TB case-finding and the use of IPT
for adults living with HIV in western Kenya. Our main
research question is as follows:
Does providing medical personnel with patient-specific
reminders regarding TB that are generated from a
patient’s electronic medical record and based on
clinical algorithms for screening significantly increase
IPT prescription rates and decrease the time from
initial encounter to IPT initiation?
This study is designed to contribute to the growing
evidence base for the use of electronic health (eHealth)
interventions to promote high-quality clinical care, health
system optimization, and positive patient outcomes.
Because this intervention is based on an open-source elec-
tronic medical record (EMR) system created specifically
for low-resource settings, it is reasonable to conclude that
positive results could be replicated in other locations that




The intervention to be studied involves providing clinic-
based medical care providers (e.g., physicians, nurses
and clinical support staff ) with patient-specific clini-
cal reminders regarding TB that are generated from a
patient’s EMR and based on accepted clinical algorithms
for TB screening and treatment.
Electronicmedical records
The back end of AMPATH’s existing clinical decision-
support system (CDSS) is an EMR system that is capable
of tracking millions of patient encounters. The AMPATH
Medical Record System (AMRS) is one of the world’s
largest implementations of the Open Medical Records
System (OpenMRS) [9]. AMRS includes more than 100
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million clinical observations from more than 300,000
patients. The system tracks data on test results, patient
history, physical exam findings, treatment plans, adher-
ence and related information from clinical encounters.
AMRS is optimized for rural western Kenya. Medi-
cal personnel complete paper encounter forms at every
patient visit, and centralized teams of data clerks enter the
data into AMRS [10]. Pilot studies are underway to guide
the transition to electronic data entry at the point of care,
but currently records are digitized centrally. This makes
it feasible to extend the coverage of the EMR system to
include the most remote facilities that do not have reliable
power or access to computers or tablets.
Clinical decision support
Prior to a patient’s next scheduled visit, clinic personnel
print a paper clinical summary sheet that gives vital details
and patient-specific care suggestions, which are automat-
ically generated by the system based on a defined set of
rules [11]. This summary sheet promotes effective task
shifting as it helps providers with modest levels of training
to provide high-quality standardized care [12].
There are currently more than 60 possible clinical
care reminders that could be triggered and printed on a
patient’s summary sheet, but there is only enough space
to display a few of the most relevant reminders for each
patient. The only TB-related reminder currently used in
the system is a reminder about the need to conduct and
report the results of a chest radiograph (CXR), which
is usually performed at the initial encounter to rule out
active pulmonary infection.
Tuberculosis clinical care reminders
As part of this study, we created a new set of reminders for
TB prevention and treatment based on accepted clinical
algorithms [13]. These reminders are designed to prompt
medical providers to complete TB screening, consider ini-
tiating anti-TB treatment or IPT, and monitor adherence
to treatment based on clinical data that exist in AMRS.
For example, if a patient does not have a history of
TB or IPT, the results of a physical examination and
patient-reported symptoms are not suggestive of active
TB, and CXR results are normal, the paper summary
sheet printed for the patient’s next visit will include the
following reminder:
Test results do NOT suggest active TB. If patient still
does NOT report TB symptoms, consider initiating
IPT. IPT is effective and could save [his/her] life.
Study design
Type of study
This will be a pragmatic, parallel-group, cluster-
randomized superiority trial involving 20 public medical
facilities in the AMPATH network in western Kenya.
Treatment group specification and assignment
Clusters will be sorted into four strata and randomly
assigned to the treatment or control group with an allo-
cation ratio of 1:1. The two stratifying variables will be
average monthly patient volume and the percentage of ini-
tial patient encounters in 2013 with CXR results recorded
in AMRS. Stratifying on cluster size is advantageous when
cluster sizes vary in the population and when cluster size
might be correlated with the endpoint of interest [14].
Stratifying on the availability of CXR results in AMRS
will potentially reduce the imbalance on a cluster-level
covariate that we expect will be related to isoniazid (INH)
prescribing behavior.
AMPATH clinical protocols advise that all patients
should have a normal CXR that is no more than 6 months
old before medical providers prescribe IPT (assuming no
other contraindications). However, in 2013, fewer than a
third of initial encounters with HIV-positive adults had
CXR results recorded in AMRS. When results are miss-
ing fromAMRS, CDSS will print a general reminder about
ordering a CXR. At best, a general reminder that prints
for most patients will potentially lead to reminder fatigue.
At worst (when CXR results exist and are known to the
provider), the prompt to order a CXR is a false positive;
in these cases, the summary sheet should contain a more
specific reminder about considering anti-TB treatment or
IPT based on the CXR result and patient symptoms, not a
reminder to order a CXR.We expect the general reminder
to order a CXR, particularly where the printing of this
reminder is a false positive, to be less impactful on INH
prescribing behavior. We also expect these messages to
be more common at facilities that are less successful in
entering CXR results into AMRS. Therefore, we will strat-
ify randomization on baseline facility-level availability of
CXR results in AMRS.
Both stratifying variables will be dichotomized (volume
greater than 1,000 patients per month and percentage of
results in AMRS greater than 23%) to create four possible
strata: low volume/low results; low volume/high results;
high volume/low results; high volume/high results.
Clinical summary sheets for patients receiving care at
treatment clusters will include the new TB care reminders
(as needed) plus the full set of existing reminders, whereas
summary sheets printed at control clusters will only
include the existing set of reminders (i.e., no new TB care
reminders).
Procedures
Following the current practice within AMPATH, clini-
cal encounter data will be recorded on standard paper
encounter forms by medical providers at the point of
care, and the existing team of data entry clerks will
enter the encounter data into AMRS. Existing data
quality personnel will continue to review the data for
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completeness and consistency and will return problem-
atic forms to cluster administrators for correction. Paper
summary sheets with clinical decision-support reminders
will be printed for each patient as usual and delivered
to facilities without on-demand printing capabilities. In
a departure from current practice, additional data clerks
will collect data on facility-level treatment compliance,
INH stock at AMPATH pharmacies, and IPT eligibility for




Medical providers with responsibility for diagnosing
TB and prescribing TB medication and IPT will be
the intervention targets for this study. Due to logisti-
cal challenges of provider randomization and concerns
about spillover between medical personnel exposed to
TB reminders and personnel in the no TB reminders
control group, medical facilities rather than individual
providers will be randomized to the treatment and control
groups.
To be included in the study as a cluster, a facility had to
meet the following criteria:
• active operations as an HIV Care Clinic
• uses AMPATH HIV initial and return encounter
forms (paper)
• enters data into AMRS or sends forms to central
location for data entry
• prints or receives printed paper clinical summary
sheets with reminders
• prescribes IPT
• classified as a mother facility in the AMPATH
networka
There are currently 22 AMPATH facilities that meet
these criteria.We decided to exclude two facilities to bring
the total number of study clusters to 20: a facility that
operates as a regional referral hospital and a small facility
that is very new to the network.
Patients
To be included in the impact analysis, patients must meet
the following criteria:
• HIV positive
• completed an adult initial encounter at a study
cluster during the enrollment periodb
• no history of TB or IPT
• attended at least one additional appointment within
90 days after the initial encounter at any study facility
Patients will not be recruited into the study, per se, as
the intervention will be provided to medical personnel
and allocated by cluster. Instead, we will run pre-specified
data queries in AMRS to identify the cohort of eligible
patients.
To be eligible for IPT, and thus eligible for our analysis,
patients must have no evidence of active TB. Since HIV-
positive adult patients in the AMPATH network typically
attend monthly medical appointments, it is reasonable
to assume that patients should be classified as eligible
for IPT or not eligible for IPT within 2 months of their
initial encounter dates. Within 3 months of the initial
encounter, patients with no evidence of active TB should
have been prescribed INH. Therefore, 3 months after each
initial encounter, patients will be classified according to
their IPT eligibility and INH prescription status at that
time.
Patients who are not eligible for IPT will be excluded
from the analysis dataset, while IPT-eligible patients will
be included. Importantly, a cluster’s failure to classify a
patient as eligible for IPT or not eligible for IPT by the
3-month mark will not exclude the patient from the anal-
ysis dataset as improving the screening and diagnostic
process is a target of the intervention. Instead, any indeter-
minate cases at the 3-month post-initial encounter mark
will be flagged by our data queries for investigation. We
anticipate that the most common reason for indetermi-
nate cases will be missing CXR results. To determine IPT
eligibility for study purposes, data clerks will investigate
all indeterminate cases and ask medical providers at the
cluster to classify the case as eligible for IPT, not eligible
for IPT, or still indeterminate. Cases ultimately deter-
mined to be eligible for IPT following this review will be
included in the analysis dataset; however, these cases will
be marked as failures on the primary INH prescription
endpoint since, without a determination of eligibility for
IPT at the 3-month mark, the patient could not initiate
IPT at that timec.
The final eligibility criterion is that a patient must attend
at least one additional appointment within 90 days of
her initial encounter so that her provider has the oppor-
tunity to be exposed to the CDSS reminders on the
summary sheet. Since a patient’s initial encounter is her
first contact with AMPATH at the facility level, there
is no summary sheet available during a patient’s initial
encounter.
Ethical considerations
This protocol has been reviewed and approved by theMoi
University School of Medicine/Moi Teaching and Referral
Hospital Institutional Research and Ethics Committee
(0001055), the Indiana University Institutional Review
Board (1307011750), and the Lifespan Research Protec-
tion Office (0000396, 00004624). The approving ethics
committees did not require individual patient consent
given the nature of the intervention.
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Statistical analysis
Study objectives as statistical hypotheses
Primary hypothesis H0 There will be no measurable
difference in the rate of INH prescriptions among IPT-
eligible patients (i.e., patients with no evidence of active
TB) who receive care from treatment or control clusters.
Ha The INH prescription rate among IPT-eligible
patients receiving care from medical providers at treat-
ment clusters will be greater than the INH prescription
rate among IPT-eligible patients receiving care frommed-
ical providers at control clusters.
Secondary hypothesis H0 There will be no measurable
difference in the time lapse from initial encounter to INH
prescription among IPT-eligible patients (i.e., patients
with no evidence of active TB) who receive care from
treatment or control clusters.
Ha The time lapse from initial encounter to INH pre-
scription among IPT-eligible patients receiving care from
medical providers at treatment clusters will be shorter
than the time lapse from initial encounter to INH pre-
scription among IPT-eligible patients receiving care from
medical providers at control clusters.
Endpoints
INH will be considered prescribed when there is an entry
in AMRS indicating that a medical provider prescribed
INH d. The denominator for the calculation of the cluster-
level prescription rate will be the number of IPT-eligible
patients in the study who completed an initial and return
encounter during the study period. The time lapse from
the date of a patient’s initial encounter to the date of INH
prescription will be calculated in days. The endpoint for
the INH prescription time lapse will be calculated by aver-
aging cluster-level INH prescription lapse means among
IPT-eligible patients across the treatment and control
groups separately.
Statistical methods
There are two main approaches to the analysis of
cluster-randomized trials: cluster-level analysis or regres-
sion analysis of individual-level observations that take
into account intracluster correlation [15]. Individual-level
regression methods are more statistically efficient and
allow for the presentation of the effects of modeled covari-
ates alongside intervention effects, but this approach may
not be robust when there are a relatively small num-
ber of clusters per arm. Therefore, we will conduct both
individual-level and cluster-level analyses.
Cluster-level summaries To determine if there is a sta-
tistically significant difference in the proportion of INH
prescriptions among IPT-eligible patients between treat-
ment and control clusters, we will use an unpaired t-test.
We will also estimate the relative risk of INH prescrip-
tion and associated 95% confidence intervals. We will
use Kaplan–Meier methods to calculate the proportion
of eligible patients receiving INH prescriptions within 3
months of their initial encounters. To test the null hypoth-
esis that there is no difference between the survival curves,
we will use the log rank test.
Individual-level regression analysis In addition to the
analyses based on cluster-level summaries, we will also use
regression models with individual-level data that account
for between-cluster variation. Specifically, we will evaluate
the reliability of logistic regression random effects models
and generalized estimating-equation approaches to model
our binary outcome. We will use Cox regression with
random effects to model the time to INH prescription.
Individual-level covariates will be limited to data collected
reliably in AMRS, such as age, gender and CD4 count.
Treatment compliance
All analyses will be on an intention-to-treat basis; thus,
we will analyze all observations based on the initial
assignment to the study arms, not compliance with the
treatment protocol. Yet, treatment compliance will be
an important construct to measure in the event of null
results so that we can distinguish between intervention
and theory failure.
Cluster-level compliance In this study, clusters (mother
sites and their satellite sites) will be randomly assigned
to receive the new TB reminders plus the existing
CDSS reminders (treatment) or just the existing CDSS
reminders (control). So to be compliant, clusters need to
print correct summary sheets, deliver the sheets to all
cluster facilities if printing is not done on-site, and ensure
that the sheets are inserted into patients’ medical files
before encounters.
A correct summary sheet is one in which TB reminders
are either present or absent depending on the cluster
treatment status. All reminders have been tested against
hundreds of patient records to ensure accuracy. Once the
trial begins, we will log all reminders printed on every
summary sheet.
The next step of the compliance chain is for facilities
to print the paper summary sheet prior to a patient’s
next encounter. Some facilities print on-site; others have
sheets delivered from the closest printing facility. Some
of the printing facilities print summary sheets on-demand
as patients arrive; others print in advance. Facilities that
have summary sheets delivered and those that print in
advance also place the papers in patient folders prior to
the encounter. For reminders to be effective, the sum-
mary sheets containing the reminders must be inserted
into a patient’s file prior to the encounter with the medical
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provider. There is no system in place currently to record
that this happens for every patient encounter.We do, how-
ever, track facility-level compliance through random spot
checks.
Medical provider behavior Medical providers could
also be a source of cluster non-compliance. For instance,
a medical provider who crosses between treatment
and control clusters would be non-compliant with her
assigned treatment status. Since nearby sites (mother and
satellite) are grouped into clusters that are then assigned
to the study arms as a cluster, we are not very con-
cerned about this possibility. Tracking where medical per-
sonnel provide care will be possible through queries of
AMRS; the location of all encounters is recorded on every
encounter form.
Another source of medical provider non-compliance
would occur when a provider does not read the summary
sheet that is placed in a patient’s file. Determining whether
or not a provider has read a summary sheet and the
reminders is a challenge. At best, we could have providers
check a box indicating that they reviewed a summary
sheet, but (a) this does not mean that a review actually
occurred and (b) we will not know what a missing check
indicates (i.e., a lack of a review or a review with a missing
check).
It is important to note that treatment compliance is not
whether providers act upon printed reminders. Rather,
provider behavior (screening for IPT eligibility and pre-
scribing INH when indicated) is part of our study end-
point.
Patient-level compliance Reminders will be adminis-
tered at the cluster level, but our primary outcome (INH
prescription) will be observed at the patient level. Like
medical providers, patients can be non-compliant if they
cross between treatment and control clusters to receive
care. However, an analysis of 2012AMPATHdata suggests
that encounters at multiple sites are rare. When multiple-
site treatment does occur, it is usually within a single
cluster of mother and satellite sites, thus avoiding the risk
of contamination. Nevertheless, encounter locations will
be tracked.
Subset analyses
Previous research in the AMPATH network suggests that
IPT initiators are more likely to be younger, female and
have a higher CD4 count. We will dichotomize each vari-
able and test for differing intervention effects in each
subgroup. We will also test the hypothesis that patients
with a greater number of reminders printed on each sum-
mary sheet will be less likely to initiate IPT compared
to patients with fewer reminders. It is possible that each
additional reminder increases the cognitive demand on a
provider and makes it more likely that the provider will
ignore the reminders.
Statistical design considerations
This will be a pragmatic, parallel-group, cluster-
randomized superiority trial with a 1:1 allocation to
treatment ratio from within four strata. Assuming a
desired power of 0.80, alpha of 0.05, 20 clusters equally
allocated to treatment and control, 50 patients per cluster,
a between-cluster coefficient of variation of 0.25 and a
baseline INH prescription rate of 15%, we will be able to
detect a minimum shift of almost 8 percentage points in
the INH prescription rate, from 15% to almost 23% using
a one-tailed teste.
Based on a recent retrospective review of AMRS data,
we believe that the current rate of INH prescription is
between 5% and 25%. Historically, this rate was higher at
nearly 40%. No matter where the true baseline rate is in
this range, our minimum detectable effect is not projected
to rise above 8 percentage points, if everything else is held
constant.
The between-cluster coefficient of variation is also
important in this calculation. Without cluster-level base-
line data on the INH prescription rate, we have to esti-
mate. This variation is often less than 0.25 and rarely
exceeds 0.50 [15]. In the previous calculations, we set the
between-cluster variation to be 0.25 and scaled it down
by 0.75 to account for the benefits of stratification. If the
between-cluster variation is really at the high end of this
range before scaling (0.50), then the minimum detectable
effect climbs to almost 12 percentage points. If we fur-
ther assume that it is only possible to observe half as many
patients per cluster (25), the minimum detectable effect
increases to 14 percentage points.
Discussion
One threat to this research design is control group con-
tamination: if patients who have an initial encounter with
a control cluster later receive care from a treatment clus-
ter, this would attenuate the treatment contrast and make
it less likely that we will detect a significant treatment
effect. Another threat is spillover effects that could occur
if medical providers stationed at treatment clusters move
to control clusters and influence clinical care at these
locations. It is not clear what the effect of this scenario
would be in practice. It is plausible that visits by treat-
ment group providers could make control group providers
more aware of TB screening and treatment, thus attenu-
ating the treatment effect. It is also plausible that visiting
treatment group providers could misinterpret the mean-
ing of the lack of TB reminders at the control location
and assume that no reminders indicates no need for TB-
related care, thus delaying or denying IPT initiation and
artificially increasing the treatment effect.
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To limit both possibilities, we will restrict eligibil-
ity to clusters with a low potential for contamination
and spillover due to geography. This should be suffi-
cient because these threats, while serious, are thought
to be low risk to begin with. For instance, an analysis
of 2012 patient encounters suggests that fewer than 9%
of patients received care at different facilities, and these
instances of movement were most likely between mother
and satellite sites within the same clusters. Incidents of
contamination and potential spillover will be tracked and
summarized.
A third threat to the research design is the loss of study
clusters. Given the relatively small number of planned
clusters, any reduction in study clusters after the start of
the trial will reduce our power to detect the effects of the
intervention. This is unlikely to be an issue.
Trial status
The reminders intervention launched on 11 April 2014
and remains active.
Endnotes
aMother facilities tend to be open more days each
week, offer more advanced services and experience
higher patient volumes than the smaller satellite facilities.
Satellite facilities tend to be staffed by the same providers
that operate the mother facilities and are located in close
geographical proximity. It is common for patients and
providers to move between a mother facility and its
associated satellite facilities.
bPatient volume over time will determine whether we
also include patients who complete an initial encounter
at a cluster’s satellite facilities.
cWe will conduct sensitivity analyses to determine if
the results change based on whether or not we also
include still indeterminate cases in the denominator of
the INH prescription rate calculation.
dWe will also attempt to collect data on IPT initiation
as measured by a patient picking up her initial batch of
INH from a pharmacy. Pharmacy records are not linked
to AMRS, however, and it is not clear that we can collect
complete and accurate data on initiation. Prescription is
a better endpoint for this study, however, as the
reminders intervention targets medical providers not
patients, and prescribing INH is a provider behavior.
eUsing Equation 7.14 for stratified cluster randomized
trials [15].
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